Directors shareholding

RNS Number : 2225V

Surgical Innovations Group PLC

10 January 2013

 



10 January 2013

Surgical Innovations Group plc

("SI" or the "Company")

Directors shareholding

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical devices, announces that it received notification yesterday that, on 8 January 2013, Douglas Liversidge, Chairman of the Company, transferred 1,000,000 ordinary shares of 1p into Quest Investments Limited. Mr Liversidge is the beneficial owner of 100% of Quest Investments Limited. Following this transaction Mr Liversidge's beneficial interest in the Company remains unchanged at 7,171,821 ordinary shares representing 1.77% of the issued share capital.

The Company also announces that it received notification yesterday that, on 8 January 2013, Graham Bowland, Chief Executive Officer of the Company, transferred 500,000 ordinary shares of 1p into his self-invested personal pension scheme. Following this transaction Mr. Bowland's beneficial interest in the Company remains unchanged at 5,028,498 ordinary shares representing 1.24% of the issued share capital.

- ENDS -

Enquiries:

Surgical Innovations Group plc	www.sigroupplc.com
Doug Liversidge, Non-Executive Chairman	Tel: [phone]
Graham Bowland, Chief Executive Officer	[e-mail]
Seymour Pierce Limited	www.seymourpierce.com
Mark Percy (Corporate Finance)	Tel: [phone]
David Banks (Corporate Broking)
Walbrook PR Ltd	Tel: [phone]
Paul McManus	Mob: [phone] or [e-mail]
Lianne Cawthorne	Mob: [phone] or [e-mail]

Notes to Editors:

About Surgical Innovations Group plc

Surgical Innovations Group plc specialises in the design and manufacture of creative solutions for minimally invasive surgery (MIS) and industrial markets. 

As well as manufacturing single-use and reusable instruments for the laparoscopic market, the Group has pioneered its flagship Resposable® instrumentation combining both single use and reusable components, ensuring ongoing revenue streams and delivering the optimum procedure performance to cost ratio.

Over 120 people are employed at the Group's 32,000 square feet facility in Leeds, with in-house design, plastic injection moulding and manufacturing equipment, producing products to the highest quality standards.

The Group's patented products are sold through three main channels:

SI brand	Through an established network of distribution partners, Surgical Innovations branded products are sold in major medical markets including North America, Britain, South East Asia, Australasia and the Indian subcontinent.
OEM and IP	The Group supplies large medical device companies on an OEM basis, generating both sales and IP royalty fees.  Clients include Teleflex Medical, Olympus and CareFusion.
Industrial	SI's patented segment technology has been applied to the industrial market enabling customers to undertake inspection and maintenance of large-scale equipment, in situ with minimum disassembly and downtime.

For more information, see www.sigrouplplc.com

 

END

 

 

RDSNKCDNNBKBFDK